Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying
2026-07-04 09:10
•Adria Cimino •The Motley Fool
••• ••• Axe Capital view
Viking Therapeutics and South Africa’s Investment Lens on Obesity Drug Hype
Bulls see Viking Therapeutics scaling towards $50 on obesity drug promise, but South African investors should stay cautious amid fierce pharma competition and pipeline risks.
Viking Therapeutics is grabbing headlines with its late-stage obesity drug VK2735, aiming to tap a massive $100 billion market. The bulls argue that positive trial data and a potential acquisition could push the stock from current levels near $37 to $50. However, given the dominance of pharmaceutical heavyweights Eli Lilly and Novo Nordisk, both with deep pockets and proven track records, Viking faces significant competition. For South African investors, the direct exposure is limited, but the USD/ZAR rate can amplify any volatility in biotech, tech, or even consumer healthcare shares such as Naspers or Prosus, given their global tech weighting and FX sensitivity. If obesity drug optimism fades globally, it would pressure the rand and local growth counters reliant on international earnings. The stock's 40% year-on-year jump signals some frothiness that warrants caution. I lean towards watching Viking closely but waiting for concrete data before committing capital. This view could turn if positive clinical results materialize or acquisition rumors intensify, igniting broader risk appetite in emerging markets including SA. this is just my opinion and not financial advice
Stay on the sidelines with Viking Therapeutics until trial outcomes are clearer; trim exposure in global tech-linked South African stocks if biotech enthusiasm wanes, while watching USD/ZAR for signals from international risk sentiment.
- USD/ZAR
- Naspers
- Prosus
- Negative trial data on VK2735
- Stronger-than-expected competitive moves from Eli Lilly and Novo Nordisk
6/10
Viking Therapeutics, a $4.3B biotech company, is developing VK2735, a weight loss drug candidate in late-stage trials. Bulls cite the massive $100B obesity drug market opportunity, potential acquisition interest, and positive historical stock reactions to data releases. Bears highlight competition from pharma giants Eli Lilly and Novo Nordisk, pipeline risk, and the stock's 40% year-over-year gain. The analyst believes the bull case outweighs the bear case, suggesting Viking could reach $50 if upcoming data proves positive.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Adria Cimino
Categories: Equities, M&A, Healthcare
Tickers: VKTX, LLY, NVO
Sentiment: Positive - The article presents a bullish outlook with the analyst concluding the bull case outweighs the bear case. The company is positioned in a high-growth $100B market with late-stage drug candidates and potential acquisition interest. Current price of $37 is seen as having room to reach $50. Mentioned as a dominant market leader in weight loss drugs with significant resources and competitive advantages. Presented as a 'safer' alternative to Viking but not the focus of the article's analysis.
Keywords: weight loss drugs, biotech, clinical trials, VK2735, obesity market, pharmaceutical competition, stock valuation
Insights:
- VKTX: Positive: The article presents a bullish outlook with the analyst concluding the bull case outweighs the bear case. The company is positioned in a high-growth $100B market with late-stage drug candidates and potential acquisition interest. Current price of $37 is seen as having room to reach $50.
- LLY: Neutral: Mentioned as a dominant market leader in weight loss drugs with significant resources and competitive advantages. Presented as a 'safer' alternative to Viking but not the focus of the article's analysis.
- NVO: Neutral: Cited as a pharma giant dominating the weight loss drug market alongside Eli Lilly. Represents competitive pressure on Viking but is presented factually without positive or negative bias.